Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV
ConditionLymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSamsung Medical Center
About this trial
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
20 years
Patients requiring systemic chemotherapy with curative intent
Written informed consent
Disqualifiers
Myeloid malignancy
Multiple myeloma
Patients do not require systemic chemotherapy with curative intent
Trial population
Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Immunochemotherapy
DrugSystemic chemotherapy with curative intent
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Reponse rate
Repsonse to the ist line treatment
Time frame
3 months after the completion of treatment2
Response
response to treatment
Time frame
3 months after chemotherapySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov